Stock listing
EIKN Stock Price, News, Filings & Events — Eikon Therapeutics, Inc.
Selected listing: EIKN · BX · CHF · CH
This page tracks Eikon Therapeutics, Inc.'s EIKN:BX listing on BX in CHF for CH, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following EIKN:BX. EIKN:BX is the stock-level entry point for investors researching Eikon Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Eikon Therapeutics, Inc. is a public company traded under the ticker EIKN in the American market. The company has a market capitalization of approximately $481.8 million. Eikon focuses on developing innovative therapeutic solutions, leveraging advanced technologies to address unmet medical needs.

- Ticker
- EIKN:BX
- Asset type
- Stock
- Market cap
- $484.2M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- BX
- Currency
- CHF
Eikon Therapeutics, Inc. EIKN:BX stock context
This page tracks Eikon Therapeutics, Inc.'s EIKN:BX listing on BX in CHF for CH, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following EIKN:BX. EIKN:BX is the stock-level entry point for investors researching Eikon Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Eikon Therapeutics, Inc. is a public company traded under the ticker EIKN in the American market. The company has a market capitalization of approximately $481.8 million. Eikon focuses on developing innovative therapeutic solutions, leveraging advanced technologies to address unmet medical needs.
Latest news from Eikon Therapeutics, Inc.
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
September 3, 2026
Eikon Therapeutics to Participate in Investor Conferences in September 2026
August 26, 2026
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
August 18, 2026
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
August 13, 2026
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
August 11, 2026
Research Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for EIKN:BX.
Eikon Therapeutics, Inc. company profile
View the public company page for Eikon Therapeutics, Inc. on 6ix.
Eikon Therapeutics, Inc. news
Read company news and market updates connected to Eikon Therapeutics, Inc..
Eikon Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Eikon Therapeutics, Inc..